Clinical Trials Browser

Pancreatic Adenocarcinoma × Taxes × Clear all

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Adenocarcinoma

NCT05624918 2025-07-31

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma

NCT02427841 2023-09-06

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase 2 Completed

20 enrolled 17 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT02562716 2022-10-19

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase 2 Completed

147 enrolled 16 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT04835064 2021-04-08

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Phase 3 Unknown

Gastrointestinal

Pancreatic Adenocarcinoma